ADMA Biologics, Inc.
ADMA
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.2B
$9.62
▲ +0.42%
P/E
13.55
Mkt Cap
$2.2B
52-Wk Range
$7.21–$20.46
52-Week Range
$7.21 - $20.46
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Specialized plasma-derived product portfolio
- Proprietary plasma collection infrastructure
- Targeted therapeutic development approach
- Established regulatory compliance in biologics manufacturing
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Expanding immunodeficiency treatment market
Value
Undervalued - trading well below Biotech & Therapeutics peers
Momentum
Strong
+19.4% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ADMA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of $0.16 vs $0.16 consensus (-2.0% surprise). Revenue of $124.4M vs $125.3M expected (-0.8%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-2.0%
Revenue trend · last 8Q
—
+59%
+40%
+14%
+12%
+18%
-0%
+2%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$119.8M
$117.5M
$114.8M
$122.0M
$134.2M
$139.2M
$114.5M
$124.4M
Margins · last 8Q
Gross
69.4%
Operating
42.2%
Profit
30.4%
Wall Street consensus
4 analysts · 75% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
75%
Hold
25%
Sell
0%
Median Price Target
—
Latest: Raymond James · Jun 10, 2026
vs Industry
How ADMA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related